Extracorporeal blood purification in the complex treatment of the novel coronavirus infection: the review of opportunities

The objective: to provide pathogenetic justification for the need for extracorporeal blood purification in the new coronavirus infection.

Results: the article analyzes guidelines and the first experience of using extracorporeal methods in the new coronavirus infection in different countries. It has been demonstrated that methods of extracorporeal blood purification have complex pleiotropic (multiple) effects and can quickly normalize the level of cytokines and other pathogenic factors, thereby preventing/reducing the severity of organ disorders. The article specifies the criteria for choosing an extracorporeal method, as well as indications for its early and late use.

1. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19). [Provisional guidelines on prevention, diagnostics and treatment of the new coronavirus infection (COVID-19)]. Version no. 7 as of 03.06.2020. http://static.consultant.ru/obj/file/doc/minzdrav_030620.pdf.

2. Klinicheskie rekomendatsii. [Guidelines]. National Society for Haemapheresis and Blood Purification. //http://www.hemapheres.ru/index.php?option=com_content&view=article&id=107&Itemid=102&lang=ru

3. Mednikov R.V. et al. Double filtration plasmapheresis (DFPP) in combined therapy for hepatitis C virus mono-infection and HCV/HIV co-infection. VICH-Infektsiya i Immunosuprssiya, 2014, vol. 6, no. 3, pp. 58-72. (In Russ.)

4. Chereshnev V.А., Chereshneva M.V. Immunologic mechanisms of local inflammation. Meditsinskaya Immunologiya, 2011, vol. 13, no. 6, pp. 557-568. (In Russ.)

5. Adeli S.H., Asghari A., Tabarraii R. et al. Using Therapeutic Plasma Exchange as a Rescue Therapy in CoVID-19 Patients: A Case Series. Pol. Arch. Intern. Med., 2020, vol. 135, pp. 455-458.

6. Alberici F., Delbarba E., Manenti C. et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int. Rep., 2020, vol. 5, pp. 580-585.

7. Büttner S., Koch B. Dolnik O. et al. Extracorporeal virus elimination for the treatment of severe ebola virus disease – first experience with lectin affinity plasmapheresis. Blood Purif., 2014, vol. 38, pp. 286-291.

8. Chen W., Lan Y., Yuan X. et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg. Microbes. Infect., 2020, vol. 9, no. 1, pp. 469-473.

9. Chen X., Zhao B., Qu Y. et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis., 2020, pp. 449.

10. Danguilan R.A. Hemoperfusion: an innovative adsorption technology for multi-organ failure. https://www.youtube.com/watch?v=9AjiFYVfuUA.

11. Dastan F., Saffaei A., Mortazavi S.M. et al. Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: a promising option for severe COVID-19. J. Glob. Antimicrob. Resist., 2020, vol. 21, pp. 340-341.

12. Dogan L., Kaya D., Sarikaya T. et al. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series. Brain, Behavior and Immunity, 2020, vol. 87, pp. 155-158.

13. Fordjour P.A., Wang Y., Shi Y. et al. Possible mechanisms of C-reactive protein mediated acute myocardial infarction. Eur. J. Pharmacology, 2015, vol. 760, pp. 72-80.

14. Fujiwara K., Kaneko S., Kakumu S. et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatology Research, 2007, vol. 37, pp. 701-710.

15. Hong K.S., Lee K.H., Chung J.H. et al. Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study. Yonsei. Med. J., 2020, vol. 61, no. 5, pp. 431-437.

16. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, no. 10223, pp. 497–506.

17. Jacofsky D., Jacofsky E.M., Jacofsky M. Understanding Antibody Testing for COVID-19. J. Arthroplasty, 2020, vol. 35, pp. 74-81.

18. Li L. Expert consensus. Application of artificial liver blood purification system in the treatment of severe and critical pneumonia caused by novel coronavirus. National Key Laboratory of Diagnosis and Treatment for Infectious Diseases, the National Center of Clinical Medical Research for Infectious Diseases. Chin. J. Clin. Infect. Dis., 2020, vol. 13, pp. E003.

19. Li T1., Lu H., Zhang W. Clinical observation and management of COVID-19 patients. Emerg. Microbes Infect., 2020, vol. 9, no. 1, pp. 687-690.

20. Liang. T. Handbook of COVID-19 Prevention and Treatment. The First Affilated Hospital, Zhejiang University School of Medicine, 2020. 68 p.

21. Lin J.-H., Chen Y.-C., Lu C.-L. et al. Application of Plasma Exchange in Association with Higher Dose CVVH in Cytokine Storm Complicating COVID-19. J. Formos. Med. Assoc., 2020, vol. 20, pp. 1116-1118.

22. Luo S., Yang L., Wang C. et al. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or Tocilizumab. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2020, vol. 49, no. 2, pp. 227-231.

23. Ma J., Xia P., Zhou Y. et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin. Immunol., 2020, vol. 214, no. 108408.

24. Mentha R., McAuley D., Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020, vol. 395, no. 10229, pp. 1033-1034.

25. Padmanabhan A., Connelly-Smith L., Aqui N., Balogun R.A., Klingel R., Meyer E., Pham H.P., Schneiderman J., Witt V., Wu Y., Zantek N.D., Dunbar N.M. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J. Clinical Apheresis, 2019, vol. 34, pp. 171-354.

26. Panigada M., Bottino N., Tagliabue P. et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost., 2020, vol. 1, pp. 1-5.

27. Ronco C., Reis T., Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir. Med., 2020, S.2213-2600(20)30229-0.

28. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens. Care Med., 2020, vol. 46, no. 5, pp. 846-848.

29. Shi H., Zhou C., He P. et al. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection. Int. J. Antimicrob. Agents, 2020, no. 105974, 20 p.

30. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 2020, vol. 18, no. 4, pp. 844-847.

31. To K.K., Tsang O.T., Leung W.S. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis., 2020, vol. 20, no. 5, pp. 565-574.

32. U.S. Food and Drug Administration. Emergency Use Authorizations. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ventilators.

33. Wichmann D., Sperhake J.P., Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann. Intern. Med., 2020, M20–2003.

34. Yang X., Sun R., Zhao M. et al. Expert recommendations on blood purification treatment protocol for patients with severe COVID-19. Recommendation and consensus. Chronic Dis. Translat. Med., 2020, vol. 6, pp. 106-114.

35. Yu L. Haemoperfusion: A promising Extracorporeal Blood Purification therapy in improving the ICU outcomes of critically ill patients with COVID-19. https://www.youtube.com/watch?v=9AjiFYVfuUA.

36. Zhang Y., Xiao M., Zhang S. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N. Engl. J. Med., 2020, vol. 382, no. 17, pp. 38.

37. Zhou F., Yu T. Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, vol. 395, no. 10229, pp. 1054-1062.

38. Zhou Ju., Zhou Ji., Shen D. et al. Development and validation of the prognostic value of ferritin in adult patients with Hemophagocytic Lymphohistiocytosis. Orphanet J. Rare Dis., 2020, vol. 15, pp. 71.